Upload
rupali-kadam
View
151
Download
3
Tags:
Embed Size (px)
Citation preview
HISTORY » THE ORIGIN OF MEDICINES » MEDICINES OF ANCIENT CIVILISATION
Medicinal preparations made from plants, animals or minerals.
Egyptians treated constipation with senna pods and caster oil.
Plants containing digital like compounds (cardiac stimulants) used to treat various ailments.
EVOLUTION OF PHARMACEUTICAL INDUSTRY
1901 :- BENGAL CHEMICALS AND PHARMA WORKS (CALCUTTA)
Advance in medical science and technology.UrbanizationPopulation GrowthMass ProductionAdvertising and mass marketing.
1902
1906
government first required to secure licenses
Pure Food and Drug Act of was passed.
:-
:-
Introduction to Indianpharmaceutical industry
Two percent of the world's pharmaceutical market.
Estimated market value of about US $8 billion. 4th rank in terms of total pharmaceutical
production. 13th in terms of value. Growing at an average rate of 7.2 %. Expected to grow to US $ 12 billion by 2010.
INDIAN PHARMACEUTICAL MARKET
DOMESTIC MARKET OVERSEAS MARKET Ethical drugs
Over the counter (OTC) drugs
Active pharmaceutical ingredient (API) market
The Export generic drugs and APIs
Contracted Research and Manufacturing Services (CRAMS)
KEY CHARACTERISTICS OF INDIAN PHARMA SECTOR
Pharmaceutical Regulatory Bodies in India
National Pharmaceutical Pricing Authority (NPPA) Central Drugs Standard and Control
Organization (CDSCO) - Department of Chemicals &
Petrochemicals (DCP)
Major Players Ranbaxy Laboratories
Dr Reddy’s Laboratories Cipla
Sun Pharma Industries Lupin Labs
(Rs 25,196.48 crore)
(Rs 4,162.25 crore)
(Rs 3,763.72 crore)
(Rs 2,463.59 crore)
(Rs 2,215.52 crore)
FACTORS LEADING TO THE GROWTH OF PHARAMACEUTICAL INDUSTRY Economic Growth
Population growth
Increase in chronic diseases
Healthcare infrastructure growth
Growth of health insurance
Low manufacturing costs
CURRENT SCENARIO
THE GROWTH SCENARIO
Role of Pharmaceutical Industry in IndiaGDP-India Advantage
Pharmaceutical Industry in India-Growth
Role of Pharmaceutical Industry in India GDP
Facts
Investment in the sector
FDI Inflow in the sector
Exports in financial years
Effect of recession
Recession Proof Business.career in the pharmaceutical industry as evergreen.fastest growing manufacturing industries
WHAT INDIA CAN OFFER TO WORLD MARKET
Contract manufacturing for Global Supply of APIs
Quality Generic Products
Process Technologies
Pharmaceutical Manufacturing Equipment
Alternate Medicines - Ayurvedic & Herbal
CHALLENGES AND OUTLOOK
• Government policies regarding range of price increase
• Increase in prices of raw materials
• Increasing competition
TARGET COMPANY COUNTRY TARGET ACQUIRER PRICE IN CRORES
Natrol US Plethico Pharma US $ 80.7mnBell, Sons and
Co(Druggist)LtdUK Marksans Pharma Ltd US$ 20-30 mn
Axicorp GmbH Germany Biocon Euro 30mn
Jamnes Robinson UK Vivemed Laboratories US$ 30 mnDowpharma UK Dr. Reddy’s Laboratories
Ltd.US $ 30 mn
Jet Generici Srl US Dr. Reddy’s Laboratories Ltd
Euro 1.5 mn
DRAXIS Health Canada Jubilant Organosys US$255 mnAlcon US Novartis AG US$11 bn
BASF’s Pharamectical
US Dr. Reddy’s Laboratories Ltd
US$40mn
SWOT ANALYSISSTRENGHTS
•Cost Competitiveness •Strong manufacturing base •Established network of laboratories and R&D infrastructure •Highly trained scientists•Strong marketing and distribution network •Rich biodiversity •Largest number of US FDA approved plants
WEAKNESSES
•Low investments in innovative R&D •Lack of resources to compete with MNCs•Inadequate regulatory standards •Production of spurious and low quality drugs spoils the image of the industry in international arena
•Significant export potential •Licensing deals with MNCs•Marketing alliances to sell MNC products in Indian market •Contract manufacturing agreements with the MNCs •Potential for developing India as a centre for international clinical trials
Opportunities Threats•Product patent regime poses serious challenge unless it invests in R&D •DPCO puts unrealistic ceilings on product prices & profitability & prevents in generating investible surpluses •Export effort hampered by procedural hurdles & non tariff barriers imposed abroad •Lowering of tariff protection
RECOMMENDATION
CORE COMPETENCIES
RIGHT PRODUCT-MIX
MERGER AND ACQUISITION
REFOCUS AND INVEST HEAVILY IN R&D.
ADVANCES IN BIOTECHNOLOGY AND INFORMATION TECHNOLOGY
FINDINGS AND CONCLUSION Between 2007-08 and 2011-12 expected CAGR might be 16%.
Export market is growing much faster than the domestic market.
Future will see strong growth in the specialty branded generics and patented drug segments.
Drugs for diabetes and cardiovascular diseases are expected to see the fastest growth among all therapy areas during 2007-2011.
Vast opportunity exists for the organized market.
Cipla, Ranbaxy and GlaxoSmithKline are controlling the top three positions in the Indian pharmaceutical market.
PHARMA DIARY…..2009,June 30 – APOLLO HOSPITALS het rises 16% to Rs.
118 Crore.2009, Aug 26 – FORTIS took over WOCKHARDT.2009, Sept 2 – RANBAXY gets TAMIFLU nod.2009, Sept 8 – SUVEN gets MILESTONE PAYMENT from
ELI LILLY.2009, Sept 11 – Is GLAXO circling Dr. REDDY.2009, Sept 11 – OGLEMILAST is not dead, not yet, says
GLENMARK chief.2009, Sept 14 – WOCKHARDT offers 65% haircut to FCCB
HOLDERS.2009, Sept 14 – REDDY’S gets US FDA nod, launches
STARLIX CLONE.
• 2009, Sept 18 – GLAXO seen in talks to pick up 5% in Dr. REDDY.
• 2009, Sept 18 - NATCO PHARMA launches anti-swine flu drug NATFLU
• 2009, Sept 20 - SUN PHARMA to file 30 applications for generic drugs in US
•
Continued…..